Citi maintains 'neutral' rating on GSK, lifts earnings forecasts as shares rise 0.31%, citing unproven Phase III pipeline and Jemperli litigation as long-term growth concerns
Citi adjusted its model after GSK's Accelerate Growth event and Q2 results. The investment bank noted GSK's £1.9 billion cost-savings drive will fund 20 Phase III trials in 2026, which Citi expects to boost earnings per share by 1% to 4% between 2027 and 2030. However, Citi flagged that external data on many upcoming trials remains thin, leading to shaky forecast foundations and a projected 2% compound annual earnings growth that is the lowest among European pharma companies. Additionally, the ongoing Jemperli litigation with AnaptysBio, with a post-trial hearing set for October 20 and a ruling expected by early 2027, also weighs on long-term growth prospects.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
JPMorgan Chase: ConvaTec Group’s earnings update is expected to dispel market concerns over achieving its 2026 guidance
-
2
White House: Trump Announces Over $17 Billion in Commercial Deals and Strategic Investments During Philippines Visit and ASEAN Summit
-
3
CoinDesk: Crypto Basis Trade Yields Near Treasuries, Talos Report Says
-
4
Korean Media: Daewoo E&C discloses delivery of immersed tube tunnel for Al Faw Grand Port to Iraq
-
5
Bloomberg: Indian Tax Officials Considering Proposal to Raise Stock Derivatives Tax and Lower Stock Transaction Tax
-
6
Bloomberg: U.S. Treasury prices edged up for a third consecutive day, supported by cooling risk appetite
-
7
UKMTO via Peninsula: Oil tanker attacked and catches fire 13 nm north of Khasab; fire extinguished, 1 person still missing
-
8
Deltaone: Target Q3 Adjusted EPS $2.65, Raises Full-Year Guidance
-
9
Anthropic Pre-IPO Crypto Futures Valuation Hits $1.7 Trillion, Exceeds Proposed IPO Cap
-
10
CNBC: Net Foreign Inflows to India Exceed $10 Billion in November, Analysts Warn Over Persistence of Inflation Impact
Markets Today
Recommended Reading


